Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma

L. V. Friedrich, R. L. White, M. B. Kays, D. S. Burgess

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The hospital, pharmacy, and antibiotic costs for patients with penetrating abdominal trauma were compared with reimbursement received; these costs were also analyzed to assess the potential impact of a total prospective pricing system (PPS). During a four-year period, 46 patients admitted solely for penetrating abdominal trauma were retrospectively evaluated: their discharge summaries indicated that, for 9 patients, reimbursement was based on diagnosis-related groups (DRGs) under the PPS; 9 patients had private insurance; and 28 were classified as 'self-paying/no insurance.' All costs, corrected for inflation, were reported in 1989 dollars. Antibiotics represented 22.5%, 1.7%, and 0.5% of pharmacy, hospital, and DRG reimbursement, respectively; pharmacy costs were 8.5% of hospital costs and 2.3% of DRG reimbursement. For all 46 patients, a net loss of $295 per patient was incurred. Four patients accounted for 43% of the hospital costs. If the hospital had been reimbursed for all of these patients by prospective pricing and DRGs, it would have had a median profit of $9730 in 42 of 46 patients. Costs exceeded DRG reimbursement in the remaining four patients by a median of $8210. Antibiotic costs and pharmacy costs represent a small portion of hospital costs and DRG reimbursement for patients with penetrating abdominal trauma; thus, cost containment efforts in these patients should be directed at other ancillary services and length of stay.

Original languageEnglish (US)
Pages (from-to)590-594
Number of pages5
JournalAmerican Journal of Hospital Pharmacy
Volume49
Issue number3
StatePublished - 1992
Externally publishedYes

Fingerprint

Pharmaceutical Economics
Diagnosis-Related Groups
Wounds and Injuries
Costs and Cost Analysis
Prospective Payment System
Hospital Costs
Therapeutics
Anti-Bacterial Agents
Insurance
Cost Control
Economic Inflation
Length of Stay

Keywords

  • Antibiotics
  • Costs
  • Diagnosis-related groups
  • Economics
  • Health care
  • Hospitals
  • Pharmacy, institutional, hospital
  • Reimbursement
  • Wounds and injuries

ASJC Scopus subject areas

  • Leadership and Management
  • Pharmaceutical Science

Cite this

Friedrich, L. V., White, R. L., Kays, M. B., & Burgess, D. S. (1992). Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma. American Journal of Hospital Pharmacy, 49(3), 590-594.

Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma. / Friedrich, L. V.; White, R. L.; Kays, M. B.; Burgess, D. S.

In: American Journal of Hospital Pharmacy, Vol. 49, No. 3, 1992, p. 590-594.

Research output: Contribution to journalArticle

Friedrich, LV, White, RL, Kays, MB & Burgess, DS 1992, 'Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma', American Journal of Hospital Pharmacy, vol. 49, no. 3, pp. 590-594.
Friedrich, L. V. ; White, R. L. ; Kays, M. B. ; Burgess, D. S. / Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma. In: American Journal of Hospital Pharmacy. 1992 ; Vol. 49, No. 3. pp. 590-594.
@article{4ff5879bc61b424097c46b1639d7f412,
title = "Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma",
abstract = "The hospital, pharmacy, and antibiotic costs for patients with penetrating abdominal trauma were compared with reimbursement received; these costs were also analyzed to assess the potential impact of a total prospective pricing system (PPS). During a four-year period, 46 patients admitted solely for penetrating abdominal trauma were retrospectively evaluated: their discharge summaries indicated that, for 9 patients, reimbursement was based on diagnosis-related groups (DRGs) under the PPS; 9 patients had private insurance; and 28 were classified as 'self-paying/no insurance.' All costs, corrected for inflation, were reported in 1989 dollars. Antibiotics represented 22.5{\%}, 1.7{\%}, and 0.5{\%} of pharmacy, hospital, and DRG reimbursement, respectively; pharmacy costs were 8.5{\%} of hospital costs and 2.3{\%} of DRG reimbursement. For all 46 patients, a net loss of $295 per patient was incurred. Four patients accounted for 43{\%} of the hospital costs. If the hospital had been reimbursed for all of these patients by prospective pricing and DRGs, it would have had a median profit of $9730 in 42 of 46 patients. Costs exceeded DRG reimbursement in the remaining four patients by a median of $8210. Antibiotic costs and pharmacy costs represent a small portion of hospital costs and DRG reimbursement for patients with penetrating abdominal trauma; thus, cost containment efforts in these patients should be directed at other ancillary services and length of stay.",
keywords = "Antibiotics, Costs, Diagnosis-related groups, Economics, Health care, Hospitals, Pharmacy, institutional, hospital, Reimbursement, Wounds and injuries",
author = "Friedrich, {L. V.} and White, {R. L.} and Kays, {M. B.} and Burgess, {D. S.}",
year = "1992",
language = "English (US)",
volume = "49",
pages = "590--594",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "3",

}

TY - JOUR

T1 - Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma

AU - Friedrich, L. V.

AU - White, R. L.

AU - Kays, M. B.

AU - Burgess, D. S.

PY - 1992

Y1 - 1992

N2 - The hospital, pharmacy, and antibiotic costs for patients with penetrating abdominal trauma were compared with reimbursement received; these costs were also analyzed to assess the potential impact of a total prospective pricing system (PPS). During a four-year period, 46 patients admitted solely for penetrating abdominal trauma were retrospectively evaluated: their discharge summaries indicated that, for 9 patients, reimbursement was based on diagnosis-related groups (DRGs) under the PPS; 9 patients had private insurance; and 28 were classified as 'self-paying/no insurance.' All costs, corrected for inflation, were reported in 1989 dollars. Antibiotics represented 22.5%, 1.7%, and 0.5% of pharmacy, hospital, and DRG reimbursement, respectively; pharmacy costs were 8.5% of hospital costs and 2.3% of DRG reimbursement. For all 46 patients, a net loss of $295 per patient was incurred. Four patients accounted for 43% of the hospital costs. If the hospital had been reimbursed for all of these patients by prospective pricing and DRGs, it would have had a median profit of $9730 in 42 of 46 patients. Costs exceeded DRG reimbursement in the remaining four patients by a median of $8210. Antibiotic costs and pharmacy costs represent a small portion of hospital costs and DRG reimbursement for patients with penetrating abdominal trauma; thus, cost containment efforts in these patients should be directed at other ancillary services and length of stay.

AB - The hospital, pharmacy, and antibiotic costs for patients with penetrating abdominal trauma were compared with reimbursement received; these costs were also analyzed to assess the potential impact of a total prospective pricing system (PPS). During a four-year period, 46 patients admitted solely for penetrating abdominal trauma were retrospectively evaluated: their discharge summaries indicated that, for 9 patients, reimbursement was based on diagnosis-related groups (DRGs) under the PPS; 9 patients had private insurance; and 28 were classified as 'self-paying/no insurance.' All costs, corrected for inflation, were reported in 1989 dollars. Antibiotics represented 22.5%, 1.7%, and 0.5% of pharmacy, hospital, and DRG reimbursement, respectively; pharmacy costs were 8.5% of hospital costs and 2.3% of DRG reimbursement. For all 46 patients, a net loss of $295 per patient was incurred. Four patients accounted for 43% of the hospital costs. If the hospital had been reimbursed for all of these patients by prospective pricing and DRGs, it would have had a median profit of $9730 in 42 of 46 patients. Costs exceeded DRG reimbursement in the remaining four patients by a median of $8210. Antibiotic costs and pharmacy costs represent a small portion of hospital costs and DRG reimbursement for patients with penetrating abdominal trauma; thus, cost containment efforts in these patients should be directed at other ancillary services and length of stay.

KW - Antibiotics

KW - Costs

KW - Diagnosis-related groups

KW - Economics

KW - Health care

KW - Hospitals

KW - Pharmacy, institutional, hospital

KW - Reimbursement

KW - Wounds and injuries

UR - http://www.scopus.com/inward/record.url?scp=0026629312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026629312&partnerID=8YFLogxK

M3 - Article

C2 - 1598932

AN - SCOPUS:0026629312

VL - 49

SP - 590

EP - 594

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 3

ER -